Soraya Benchikh El Fegoun

CSL (Switzerland) — Switzerland

Medicine · Health Sciences

6h-index225citations16works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hemophilia Treatment and Research(14), Platelet Disorders and Treatments(7), Blood Coagulation and Thrombosis Mechanisms(7), Hemostasis and retained surgical items(4), Coagulation, Bradykinin, Polyphosphates, and Angioedema(3)

Publications16 total

Patient Insights into and Satisfaction with Treatment, Management, and Clinical Research of Hereditary Hemochromatosis
Therapeutic Innovation & Regulatory Science·2025
PB0854 Could Gynecologists Contribute to an Increased Diagnosis of von Willebrand Disease among Women with Heavy Menstrual Bleeding?
Research and Practice in Thrombosis and Haemostasis·2023Open Access
PB1296 A Prospective, Non-Interventional Study to Investigate the Effectiveness of rVIII-SingleChain in Patients with Hemophilia A
Research and Practice in Thrombosis and Haemostasis·2023Open Access
Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response
Thrombosis and Haemostasis·2021· 5 citedOpen Access
Post‐hoc analysis on the long‐term response to fixed‐dose prophylaxis with N8‐GP in patients with haemophilia A
Haemophilia·2021· 1 citedOpen Access
A survey among patients with haemophilia and inhibitors or their caregivers, seeking treatment in non‐haemophilia treatment centres
Haemophilia·2020· 1 cited
Barriers and challenges for the fast treatment of bleeds in the non‐haemophilia treatment centre hospital setting
Haemophilia·2020· 5 cited
Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement
Haemophilia·2019· 36 citedOpen Access
Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program
Journal of Thrombosis and Haemostasis·2019· 62 cited
HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries
TH Open·2019· 23 citedOpen Access
Recombinant activated factor <scp>VII</scp> in approved indications: Update on safety
Haemophilia·2018· 9 citedOpen Access
Methodologies for data collection in congenital haemophilia with inhibitors (<scp>CH</scp>wI): critical assessment of the literature and lessons learned from recombinant factor <scp>VII</scp>a
Haemophilia·2018· 3 cited
Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia a or B with Inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-Interventional SMART-7™ Study
Blood·2016
Home treatment of haemarthrosis with recombinant activated factor VII in patients with haemophilia A or B and inhibitors
Blood Coagulation & Fibrinolysis·2016· 4 citedOpen Access
Safety update on the use of recombinant activated factor VII in approved indications
Blood Reviews·2015· 50 cited
The use of recombinant activated factor VII in patients with acquired haemophilia
Blood Reviews·2015· 26 cited

Frequent Co-authors

Stephanie Seremetis(4), Andreas Tiede(4), Víctor Jiménez‐Yuste(3), Ellis J. Neufeld(2), Claude Négrier(2), Per Arkhammar(2), Anders Rosholm(2), Kagehiro Amano(2), Gary Benson(2), Craig M. Kessler(2), Yasser Wali(2), Hossam Saad(2), Pratima Chowdary(2), K. K. Hampton(2), Guy Young(2), Philippe de Moerloose(2), Joanna A. Davis(2), Richard Habis(2), Robert Klamroth(2), Gallia G. Levy(1)